Steven Arkin
Pfizer (United States)(US)
Publications by Year
Research Areas
Hemophilia Treatment and Research, Chronic Myeloid Leukemia Treatments, Blood Coagulation and Thrombosis Mechanisms, Platelet Disorders and Treatments, Hemoglobinopathies and Related Disorders
Most-Cited Works
- → Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors(1993)493 cited
- → Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib(2011)458 cited
- → Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations(2014)327 cited
- → Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A(1990)264 cited
- → Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A(1993)182 cited
- → Loss of high‐responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi‐center hemophilia cohort study(1993)116 cited
- → Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII(2009)93 cited
- → Effects of stathmin inhibition on the mitotic spindle(2001)81 cited
- → Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors(1998)75 cited
- → Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease(2017)74 cited